AR065651A1 - DIHIDRO Y TETRAHIDRO OXAZOLO[3, 2-A]PIRIMIDIN-7-ONAS SUSTITUíDAS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO COMO MODULADORES ALOSTÉRICOS DE MGLUR2. - Google Patents
DIHIDRO Y TETRAHIDRO OXAZOLO[3, 2-A]PIRIMIDIN-7-ONAS SUSTITUíDAS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO COMO MODULADORES ALOSTÉRICOS DE MGLUR2.Info
- Publication number
- AR065651A1 AR065651A1 ARP080100958A ARP080100958A AR065651A1 AR 065651 A1 AR065651 A1 AR 065651A1 AR P080100958 A ARP080100958 A AR P080100958A AR P080100958 A ARP080100958 A AR P080100958A AR 065651 A1 AR065651 A1 AR 065651A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- mono
- cr9r10
- Prior art date
Links
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 2
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- -1 benzocycloheptanyl Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 abstract 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 abstract 1
- CYWXIIXFGLXHMD-UHFFFAOYSA-N 2-(phenoxymethyl)-2,3,5,6-tetrahydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one Chemical compound O1C2=NC(=O)CCN2CC1COC1=CC=CC=C1 CYWXIIXFGLXHMD-UHFFFAOYSA-N 0.000 abstract 1
- JSHKPOGQAOKGDX-UHFFFAOYSA-N 2-(phenoxymethyl)-2,3-dihydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one Chemical compound O1C2=NC(=O)C=CN2CC1COC1=CC=CC=C1 JSHKPOGQAOKGDX-UHFFFAOYSA-N 0.000 abstract 1
- WSMJHHLEGIXYSS-UHFFFAOYSA-N 2-[(2-methylphenoxy)methyl]-2,3-dihydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one Chemical compound CC1=CC=CC=C1OCC1OC2=NC(=O)C=CN2C1 WSMJHHLEGIXYSS-UHFFFAOYSA-N 0.000 abstract 1
- LFVCGUXZQMQTAM-UHFFFAOYSA-N 5-methyl-2-(phenoxymethyl)-2,3,5,6-tetrahydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one Chemical compound C1N2C(C)CC(=O)N=C2OC1COC1=CC=CC=C1 LFVCGUXZQMQTAM-UHFFFAOYSA-N 0.000 abstract 1
- STNLDAKERXMCOK-UHFFFAOYSA-N 5-methyl-2-[(2-methylphenoxy)methyl]-2,3-dihydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one Chemical compound CC1=CC=CC=C1OCC1OC2=NC(=O)C=C(C)N2C1 STNLDAKERXMCOK-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Estos compuestos son moduladores alostéricos de receptores de glutamato metabotropico (mGluR), particularmente, el receptor de mGluR2 por lo tanto son utiles como agentes farmacéuticos, especialmente en el tratamiento y/o prevencion de una diversidad de trastornos del sistema nervioso central (SNC), incluyendo, pero sin limitacion, afecciones neurodegenerativas agudas y cronicas, psicosis, convulsiones, ansiedad, depresion, migrana, dolor, trastornos del sueno y emesis. Reivindicacion 1: Un compuesto de la formula (1) en la que: la línea de puntos es un enlace sencillo o un doble enlace; p es 0 o 1; n es un numero entero de 0 a 3; X es oxígeno, azufre o NR21, donde R21 es hidrogeno o alquilo C1-4; Y es oxígeno o azufre; R1 y R2 son iguales o diferentes y cada uno de ellos se selecciona, independientemente entre sí, entre el grupo que consiste en hidrogeno, CF3, alquilo C1-10 de cadena lineal o ramificada, mono o di-fluoroalquilo C1-4, mono- o di-fluoroalcoxi C1-4-alquilo C0-4, mono- o di-fluoroalquilsulfanil C1-4-alquilo C0-4, mono- o di-fluoroalquilsulfinil C1-4-alquilo C0-4, mono- o di-fluoroalquilsulfonil C1-4-alquilo C0-4, alcoxi C1-10-alquilo C0-4, alquilsulfanil C1-10-alquilo C0-4, alquilsulfinil C1-10-alquilo C0-4, alquilsulfonil C1-10-alquilo C0-4, alcoxi C1-10-mono- o di-fluoroalquilo C1-4, alquilsulfanil C1-10-mono- o di-fluoroalquilo C1-4, alquilsulfinil C1-10-mono- o di-fluoroalquilo C1-4, alquilsulfonil C1-10-mono- o di-fluoroalquilo C1-4, aril C6-10-alquilo C0-4, ariloxi C6-10-alquilo C0-4, arilsulfanil C6-10-alquilo C0-4, arilsulfinil C6-10-alquilo C0-4, arilsulfonil C6-10-alquilo C0-4, cicloalquil C3-8-alquilo C0-4, cicloalcoxi C3-8-alquilo C0-4, cicloalquilsulfanil C3-8-alquilo C0-4, cicloalquilsulfinil C3-8-alquilo C0-4, cicloalquilsulfonil C3-8-alquilo C0-4, hidroxialquilo C1-4, heteroarilalquilo C0-4, heteroariloxialquilo C0-4, heteroarilsulfanilalquilo C0-4, heteroarilsulfinilalquilo C0-4, heteroarilsulfonilalquilo C0-4, heterociclil-alquilo C0-4 saturado, heterocicliloxi-alquilo C0-4 saturado, heterociclilsulfanil-alquilo C0-4 saturado, heterociclilsulfinil-alquilo C0-4, heterociclilsulfonil-alquilo C0-4, -CO2R22 o -CONR23R24, donde R22, R23 y R24 son iguales o diferentes y cada uno de ellos se selecciona, independientemente entre sí, entre hidrogeno o alquilo C1-4; R3 y R4 son iguales o diferentes y cada uno de ellos se selecciona, independientemente entre sí, entre el grupo que consiste en hidrogeno, alquilo C1-4 y aril C6-10-alquilo C1-4; o R3 y R4 tomados junto con el átomo de carbono al que están unidos forman un anillo carbocíclico C5-7 sustituido o sin sustituir; R5, R6 y R7 son iguales o diferentes y cada uno de ellos se selecciona, independientemente entre sí, entre el grupo que consiste en hidrogeno y alquilo C1-4; R8 se selecciona entre el grupo que consiste en fenilo sustituido o sin sustituir, naftilo sustituido o sin sustituir, indanilo sustituido o sin sustituir, tetralinilo sustituido o sin sustituir, benzocicloheptanilo sustituido o sin sustituir, hexahidrofluorenilo sustituido o sin sustituir, cicloalquilo C3-8 sustituido o sin sustituir, furanilo sustituido o sin sustituir, benzofuranilo sustituido o sin sustituir, tiofenilo sustituido o sin sustituir, benzotiofenilo sustituido o sin sustituir, indolilo sustituido o sin sustituir, benzotiazolilo sustituido o sin sustituir, tiazolilo sustituido o sin sustituir, pirrolilo sustituido o sin sustituir, piridilo sustituido o sin sustituir, tetrahidroisoquinolinilo sustituido o sin sustituir, tetrahidroquinolinilo sustituido o sin sustituir, isoquinolinilo sustituido o sin sustituir, quinolinilo sustituido o sin sustituir, tetrahidrodibenzofuranilo sustituido o sin sustituir y hexahidrodibenzofuranilo sustituido o sin sustituir; donde dichos sustituyentes se seleccionan entre el grupo que consiste en CF3, OCF3, halogeno, CN, SF5, alquilo C1-20 de cadena lineal o ramificada, alquilsulfonilo C1-4, cicloalquil C3-10-(CR9R10)m sustituido o sin sustituir, espiro-cicloalquilo C6-16 sustituido o sin sustituir, aril C6-10-(CR9R10)m sustituido o sin sustituir, heteroaril-(CR9R10)m sustituido o sin sustituir, aril C6-10-cicloalquilo C3-8 sustituido o sin sustituir, un grupo bicíclico C8-13 sustituido o sin sustituir, adamantilo sustituido o sin sustituir, indanilo sustituido o sin sustituir, tetralinilo sustituido o sin sustituir, benzocicloheptilo sustituido o sin sustituir, alcoxi C1-20 de cadena lineal o ramificada, cicloalcoxi C3-10 sustituido o sin sustituir, ariloxi C6-10 sustituido o sin sustituir, heteroariloxi sustituido o sin sustituir, piperidinil-(CR9R10)m sustituido o sin sustituir, piperazinil-(CR9R10)m sustituido o sin sustituir, lactama C4-7 sustituido o sin sustituir, tetrahidropiranil-(CR9R10)m sustituido o sin sustituir, tetrahidrofuranoil-(CR9R10)m sustituido o sin sustituir, 1,3-dioxanilo sustituido o sin sustituir, 1,3-dioxolanilo sustituido o sin sustituir, alcoxietoxi C1-4, cicloalquiloxietoxi C3-8 sustituido o sin sustituir, ariloxietoxi C6-10 sustituido o sin sustituir y heteroariloxietoxi sustituido o sin sustituir; donde m es un numero entero de 0 a 10; R9 y R10 son iguales o diferentes y se eligen, independientemente entre sí, entre hidrogeno o alquilo C1-4; o R9 y R10 tomados junto con el átomo de carbono al que están unidos forman un anillo carbocíclico C3-8 sustituido o sin sustituir; y donde dichos sustituyentes se seleccionan entre los sustituyentes mencionados anteriormente; o una sal del mismo, o un enantiomero, estereoisomero o un tautomero del mismo, o una mezcla racémica de los mismos; y con la excepcion de los siguientes compuestos: 2-(2-metil-fenoximetil)-2,3-dihidro-oxazolo[3,2-a]pirimidin-7-ona; 5-metil-2-(2-metil-fenoximetil)-2,3-dihidro-oxazolo[3,2-a]pirimidin-7-ona; 2-(fenoximetil)-2,3-dihidro-oxazolo[3,2-a]pirimidin-7-ona; 5-metil-2-fenoximetil-2,3,5,6-tetrahidro-oxazolo[3,2-a]pirimidin-7-ona; y 2-fenoximetil-2,3,5,6-tetrahidro-oxazolo[3,2-a]pirimidin-7-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89399107P | 2007-03-09 | 2007-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065651A1 true AR065651A1 (es) | 2009-06-24 |
Family
ID=39760318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100958A AR065651A1 (es) | 2007-03-09 | 2008-03-07 | DIHIDRO Y TETRAHIDRO OXAZOLO[3, 2-A]PIRIMIDIN-7-ONAS SUSTITUíDAS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO COMO MODULADORES ALOSTÉRICOS DE MGLUR2. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8642603B2 (es) |
| EP (1) | EP2137193B1 (es) |
| JP (1) | JP5351056B2 (es) |
| KR (1) | KR101547573B1 (es) |
| CN (2) | CN101675060A (es) |
| AR (1) | AR065651A1 (es) |
| AU (1) | AU2008226649B2 (es) |
| BR (1) | BRPI0808678A2 (es) |
| CA (1) | CA2680262C (es) |
| CL (1) | CL2008000691A1 (es) |
| CO (1) | CO6231034A2 (es) |
| IL (1) | IL200695A (es) |
| MA (1) | MA31285B1 (es) |
| MX (1) | MX2009009447A (es) |
| MY (1) | MY147757A (es) |
| NZ (1) | NZ579431A (es) |
| PE (1) | PE20090158A1 (es) |
| RU (1) | RU2470937C2 (es) |
| SG (2) | SG10201506994RA (es) |
| TW (1) | TWI417296B (es) |
| UY (1) | UY30954A1 (es) |
| WO (1) | WO2008112483A2 (es) |
| ZA (1) | ZA200905564B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| SG10201506994RA (en) | 2007-03-09 | 2015-10-29 | Sanofi Aventis | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| DE602008004794D1 (de) | 2007-09-14 | 2011-03-10 | Addex Pharmaceuticals Sa | 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one |
| AU2008297877C1 (en) | 2007-09-14 | 2013-11-07 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones |
| US8207181B2 (en) | 2008-03-06 | 2012-06-26 | Sanofi | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof |
| EP2268645B1 (en) * | 2008-03-06 | 2014-11-12 | Sanofi | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102186477B (zh) | 2008-10-16 | 2013-07-17 | 奥梅-杨森制药有限公司 | 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物 |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| AR076861A1 (es) | 2009-05-12 | 2011-07-13 | Addex Pharma Sa | Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2 |
| WO2010130422A1 (en) | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| AU2010278779B2 (en) * | 2009-07-31 | 2014-08-14 | Global Alliance For Tb Drug Development | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses |
| AR078172A1 (es) | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur |
| AR078171A1 (es) * | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas |
| AR078173A1 (es) | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso |
| EP2563143A4 (en) | 2010-04-29 | 2013-09-25 | Merck Sharp & Dohme | SUBSTITUTED 1,3-BENZOTHIAZOL-2 (3H) -ONE AND [1,3-] THIAZOLO- [5,4-B] PYRIDINE-2 (-1H) -ONE AS POSITIVE ALLOSTERE MODULATORS OF MGLUR2 |
| EP2611298A4 (en) * | 2010-08-31 | 2014-07-30 | Univ Vanderbilt | BICYCLIC OXAZOLE AND THIAZOL COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR-5 RECEPTORS |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| CA2820262A1 (en) | 2010-12-08 | 2012-06-14 | Vanderbilt University | Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors |
| JP2015006994A (ja) * | 2011-10-28 | 2015-01-15 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| SMT201900545T1 (it) | 2014-01-21 | 2019-11-13 | Janssen Pharmaceutica Nv | Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo |
| PH12019500127B1 (en) | 2014-01-21 | 2022-05-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| US11247998B2 (en) | 2017-07-27 | 2022-02-15 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| EP3604320A1 (de) | 2018-08-01 | 2020-02-05 | Covestro Deutschland AG | Phosphorfunktionelle polyoxyalkylenpolyole und verfahren zu deren herstellung |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN115477607B (zh) * | 2022-10-14 | 2024-05-24 | 肖尖 | 一种光稳定剂中间体及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH517064A (de) * | 1969-07-09 | 1971-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten |
| FR2724171B1 (fr) * | 1994-09-05 | 1997-01-03 | Synthelabo | Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique |
| DE60214138T2 (de) | 2001-02-21 | 2007-03-29 | Janssen Pharmaceutica N.V. | Isoxazolin-derivate als antidepressiva |
| US7476673B2 (en) * | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7786888B2 (en) * | 2006-10-30 | 2010-08-31 | Honeywell International Inc. | False ceiling fire detector assembly |
| SG10201506994RA (en) | 2007-03-09 | 2015-10-29 | Sanofi Aventis | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| AR078171A1 (es) | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas |
-
2008
- 2008-03-06 SG SG10201506994RA patent/SG10201506994RA/en unknown
- 2008-03-06 RU RU2009137369/04A patent/RU2470937C2/ru not_active IP Right Cessation
- 2008-03-06 AU AU2008226649A patent/AU2008226649B2/en not_active Ceased
- 2008-03-06 BR BRPI0808678-8A patent/BRPI0808678A2/pt not_active IP Right Cessation
- 2008-03-06 CN CN200880015025A patent/CN101675060A/zh active Pending
- 2008-03-06 MX MX2009009447A patent/MX2009009447A/es active IP Right Grant
- 2008-03-06 MY MYPI20093541A patent/MY147757A/en unknown
- 2008-03-06 SG SG2012016507A patent/SG179453A1/en unknown
- 2008-03-06 EP EP08731502.4A patent/EP2137193B1/en not_active Not-in-force
- 2008-03-06 CN CN201410643097.8A patent/CN104447792A/zh active Pending
- 2008-03-06 KR KR1020097021205A patent/KR101547573B1/ko not_active Expired - Fee Related
- 2008-03-06 WO PCT/US2008/056002 patent/WO2008112483A2/en not_active Ceased
- 2008-03-06 JP JP2009552879A patent/JP5351056B2/ja not_active Expired - Fee Related
- 2008-03-06 NZ NZ579431A patent/NZ579431A/en not_active IP Right Cessation
- 2008-03-06 CA CA2680262A patent/CA2680262C/en not_active Expired - Fee Related
- 2008-03-07 CL CL200800691A patent/CL2008000691A1/es unknown
- 2008-03-07 PE PE2008000442A patent/PE20090158A1/es not_active Application Discontinuation
- 2008-03-07 UY UY30954A patent/UY30954A1/es not_active Application Discontinuation
- 2008-03-07 TW TW097107968A patent/TWI417296B/zh not_active IP Right Cessation
- 2008-03-07 AR ARP080100958A patent/AR065651A1/es not_active Application Discontinuation
-
2009
- 2009-08-11 ZA ZA200905564A patent/ZA200905564B/xx unknown
- 2009-09-02 IL IL200695A patent/IL200695A/en not_active IP Right Cessation
- 2009-09-04 US US12/554,129 patent/US8642603B2/en not_active Expired - Fee Related
- 2009-09-09 CO CO09096629A patent/CO6231034A2/es active IP Right Grant
- 2009-10-01 MA MA32239A patent/MA31285B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065651A1 (es) | DIHIDRO Y TETRAHIDRO OXAZOLO[3, 2-A]PIRIMIDIN-7-ONAS SUSTITUíDAS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO COMO MODULADORES ALOSTÉRICOS DE MGLUR2. | |
| AR071284A1 (es) | Compuestos heterociclicos con uniones puente y metodos para usarlos | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR071285A1 (es) | Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. | |
| PE20020510A1 (es) | DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT) | |
| AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
| AR044038A1 (es) | Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| AR044037A1 (es) | Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| AR078171A1 (es) | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR046309A1 (es) | Derivados de dihidrobenzofuranilo alcanamina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos del sistema nervioso central. | |
| CA2567343A1 (en) | N-cyclic sulfonamido inhibitors of gamma secretase | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| AR058381A1 (es) | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica | |
| AR053548A1 (es) | Derivados de oxiindol | |
| AR067991A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptores de nk3 | |
| AR074558A1 (es) | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 | |
| AR046603A1 (es) | Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc | |
| AR039957A1 (es) | Derivados de 1-sulfonil-4-aminoalcoxi indol, metodos de preparacion y composicion farmaceutica | |
| PE20050435A1 (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos | |
| MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |